Greg Allison, M.D.
Newark, NJ (USA)
Role(s):
C-Level Executive (CEO, CFO, etc.)
HealthMed Corp
Find More Startups
Startup
Location:
Newark
Industry:
Pharmaceuticals
Year Founded:
2013
Number Employees:
1-10 people
Business Stage:
Growth (not profitable)
Entity Type:
"C" Corporation
Description:
HealthMed is a new generation pharmaceutical company, dedicated to developing healthier medicines. We redirect the potency of your prescriptions, harvesting them for powerful uses in prevention. HM-100, a "polypill" for primary prevention, is on track for 505(b)(2) application. The HM-100 development timeline includes FDA Three-Year Exclusivity for a New Drug Application that contains sponsored clinical studies essential to its approval, and FDA Priority Review for a New Drug Application to include documented evidence of likely improvements in adherence.
The cardiovascular polypill is a combination of low-dose blood pressure medicines and a cholesterol medicine, plus or minus aspirin. HealthMed's combinations are transformative in that they harbor broad potential to effectively eliminate adherence difficulties in cardiovascular polypharmacy: now a widespread, life-threatening concern. Our combinations offer cost savings to the consumer and to other payers in the health care system. They extend convenience of prescription for patient, provider, health care worker and pharmacist. We offer de-risked, branded products that may each be developed in 24 months, for a reasonable initial investment. HM-100, our initial product, contains a single-dose moderate statin and two low-dose antihypertensives, targeted toward the primary prevention of cardiovascular disease.